250-403 Related Links

250-403 Killexams-Blog  |   250-403 Blogspot  |   250-403 Dropmark-Text  |   250-403 RSS Feed  |   250-403 ge.tt  |   250-403 4shared PDF  |   250-403 files.fm   |   250-403 4shared  |   250-403 coursehero.com  |   250-403 ello.co  |   250-403 clipsharelive.com   |   250-403 blogdigy.com  |   250-403 Youtube  |   250-403 sites.google.com  |   250-403 justpaste.it/  |   250-403 Instapaper  |   250-403 spaces.hightail.com  |  
Do not forgt these Symantec 250-403 Questions before test - Killexams

How long practice is required for 250-403 test?

250-403 PDF Questions | 250-403 brain dumps | 250-403 test prep | 250-403 sample test | 250-403 cheat sheet - Killexams.com



250-403 - Administration of Symantec(TM) Management Platform 7.1 - Dump Information

Vendor : Symantec
Exam Code : 250-403
Exam Name : Administration of Symantec(TM) Management Platform 7.1
Questions and Answers : 174 Q & A
Updated On : Click to Check Update
PDF Download Mirror : 250-403 Brain Dump
Get Full Version : Pass4sure 250-403 Full Version


a way to put together for 250-403 examination?

I am very much happy together with your test papers specially with the answered issues. Your test papers gave me the courage to appear in the 250-403 exam with self-belief. The result is 79%. all over again I entire heartedly thank the Killexams organization. A no different way to pass the 250-403 exam other than Killexams braindumps. I passed different tests with the help of Killexams questions bank. I endorse it to each one. If you just needed to pass 250-403 exam. Then take Killexams assistance.

clearly incredible revel in!

I am saying from my enjoy that in case you remedy the query papers one after the other then you will crack the exam. Killexams has very powerful test material. Such a completely useful and helpful internet site. thanks, crew Killexams.

Take a smart circulate, achieve these 250-403 questions and answers.

I fantastically propose this package deal to each person making plans to get 250-403 questions and answers. Exams for this certification are tough, and it takes some work to pass them. Killexams does the maximum of it for you. 250-403 exam I was given from this Internet site had a maximum of the questions provided during the exam. Without the ones dumps, I anticipate I would fail, and that is why such lots of people do not pass 250-403 exam from the primary attempt.

It is unbelieveable, but 250-403 real exam questions are availabe here.

I would like to spread the word about this certainly one-of-a-kind and truly tremendous Killexams which helped me in acting outstandingly well in my 250-403 exam and exceeding all expectations. I could say that Killexams is one of the maximum admirable online teaching ventures

I sense very assured via getting ready 250-403 real exam questions.

It turned into just 12 days to attempt for the 250-403 exam and I used to be loaded with some points. I used to be seeking an easy and effective guide urgently. I was given the Questions and Answers of Killexams. Its quick answers had been no longer tough to finish in 15 days. within the authentic 250-403 exam, I scored 88%, noting all of the questions in due time, and was given 90% questions like the pattern papers that they supplied. an awful lot obliged to Killexams.

What is easiest way to pass 250-403 exam?

There will be one subject matter Differentiate 250-403 exam which will be very steely and difficult for me but Killexams succor me in elapsing me that. It turned remarkable to peer that more element questions of the actual exams were normal from the aide. I was searching for some exam results. I associated the Questions and Answers from Killexams to get my-self prepared for the exam 250-403. A score of 85% in 58 questions. many ways to you.

Dont forget to try these real exam questions for 250-403 exam.

I was given 79% in the 250-403 Exam. Your test dump turned into very beneficial. A huge Thank you Killexams!

wherein will I discover material for 250-403 examination?

This is my first time that I took this company. I experience very assured in 250-403 but. I prepare my 250-403 the use of questions and answers with exam simulator software through the Killexams team.

wherein can i am getting understanding of 250-403 exam?

So, a few months later, after I received a large promotion with even larger obligations, I frequently find myself drawing from the knowledge I was given from Killexams. So it also facilitates ultimately, so I do not experience that guilty anymore.

I need Latest and updated dumps of 250-403 exam.

Killexams questions and answers helped me to know what exactly is anticipated in the exam 250-403. I prepared well within 10 days of coaching and completed all the questions of the exam in eighty mins. It incorporates the subjects much like exam factor of view and makes you memorize all the subjects easily and as it should be. It also helped me to recognize the way to manipulate the time to complete the exam earlier than time. It is a great approach.

See more Symantec dumps

250-412 | 250-407 | 250-316 | 250-270 | 250-250 | ST0-248 | 250-315 | 250-254 | 250-272 | ST0-172 | 250-401 | ST0-306 | ST0-148 | 250-314 | ST0-155 | 250-411 | 200-309 | ST0-247 | ST0-173 | ST0-141 | 250-511 | 250-505 | 250-370 | 250-255 | 250-410 | ST0-237 | 250-406 | ST0-200 | ST0-118 | 250-271 | 250-371 | ST0-192 | 850-001 | ST0-202 | ST0-149 | ST0-135 | 250-428 | 250-512 | 250-403 | ST0-303 | ST0-304 | ST0-174 | 250-252 | 250-352 | 250-351 | ST0-085 | ST0-250 | 250-251 | ST0-134 | ST0-147 |

Latest Exams added on Killexams

PCAP-31-03 Answers Bank | SOA-C02 dumps pdf | CQA official cert guide pdf | OCS free test engine | DP-203 accurate questions | EXIN-ITILF elearningexams | CV1-003 exam cost | iSAQB-CPSA-F new questions | HPE6-A70 passing score | 300-610 download | 701-100 vce exam simulator | APD01 lab questions | PEGAPCRSA80V1_2019 case study | CPIM mock exam | WorkKeys Sample exam | 77-420 certificationking | CS0-002 dumps in pdf | IAPP-CIPP-E study guide | H19-307 best study techniques | RDN study help | GASF test prep online | ACE-A1.2 answers | 300-435 examcollection | RE18 new questions | HPE6-A68 training tips | 2V0-21.20 pass-guaranteed | 300-535 Question Answer Bank | Google-PCE download | HPE6-A82 exam cost | DTR exam | JN0-347 kit | COG-385 amazon | AZ-304 exam voucher | CBBF vce exam simulator | GMAT-Quntitative full version | GMAT-Verbal dump | QQ0-200 accurate answers | NSE4_FGT-6.4 answers | DES-1D12 questions and answers | CSLE exam dumps | MCPA-Level-1 mock exam | LFCS is percent of | Magento-2-CAD cert guide | CFA-Level-III official certification guide | 9A0-080 MCQ | MS-203 vce files | COMLEX-USA official cert guide | 200-201 academic edition | 1Y0-440 elearningexams | QSBA2018 free ebook | 300-715 troytec | NBCC-NCC made easy | CLTD premium vce file | AZ-204 simulator download | VMCE2020 pdf download | ECSAv10 book pdf | AD0-E106 exam | Mulesoft-CD actual test | HD0-200 study material | MCIA-Level-1 study guide pdf | NSE8-811 dumps | MO-201 guaranteed success | ATA practice test | NREMT-NRP pass4sure dumps | 350-901 correct answers | PRF study material | 4A0-101 testking pdf | 3313 new questions | Servicenow-CIS-HR training videos | CWDP-303 test prep | 830-01 transcender | ANS-C00 pdf download | SPLK-2002 premium vce file | PL-200 mock | SY0-601 passing score | 1D0-61C ebook | SD0-302 results | CCSK exambraindumps | 98-388 official cert guide | ADM211 passcertification | T1-GR1 ebook | 4A0-103 exam voucher | 4A0-104 free book | IIA-CIA-Part3 accurate questions | Watchguard-Essentials examcollection | 200-901 pearson vue | Servicenow-CAD examsokay | DOP-C01 boson practice | 300-420 actual test pdf | 4A0-N02 latest dumps | 300-810 questions & answers | IAPP-CIPT lab kit | C2090-011 dumps pdf | ITIL-Practitioner study help | 300-820 Sample Test Questions | JN0-1301 Questions Bank | 2V0-61.20 pdf download | NCCT-TSC pass4sure | NCMA-CMA study guide | PEGAPCSSA80V1_2019 test-king | C2010-597 vce free | 101-500 guide | 102-500 cert guide | COMPASS pdf | DA-100 online test | WHNP actual test pdf | Salesforce.Field-Service-Lightning-Consultant lab kit | SPLK-1003 practice test | 350-501 camp | CDCA-ADEX test prep online | DES-6332 official cert guide library | CWNA-108 mock | IAPP-CIPM answers | Servicenow-CIS-RC difficulty | 300-425 book download | MS-700 Sample Question and Answer | ACP-600 exam cost | IQ0-100 academic edition | C1000-026 pass tricks | C9560-503 new questions | MB-240 sybex | Servicenow-CIS-CSM aio testking | Platform-App-Builder vce exam simulator | JN0-1101 Quiz | LCAC questions answers pdf | SCS-C01 free answers | AD0-E104 test-king | ABPN-VNE examcollection | E20-594 dumps free download pdf | DES-4421 test questions | AZ-104 exam cram | SPLK-1001 best study techniques | RPFT cheat sheet | PL-900 actualtests | C2180-410 examsokay | 1D0-525 simulator | AWS-CDBS questions answers pdf | SAA-C02 dumps in pdf | ABCTE guide | SPLK-1002 exam cram | DES-2T13 dumps pdf | AZ-303 questions and answers | 4A0-C01 exam tricks | PR000041 kindle | 300-415 free e-book | ISEB-SWT2 Sample exam | PCIP3-0 ebook | NAB-NHA study guide | ASVAB-Electronic-Info pdf download | HPE0-V14 answers | CTAL-TM-001 pass4sure | 300-410 pass score | ASVAB-Word-Knowledge best study techniques | CAMS exam guide | NS0-160 objectives | DEA-1TT4 kindle | QV12BA downloads | 300-430 sparknotes | DVA-C01 pdf download | NLN-PAX how many questions | PANRE questions & answers | DES-1B31 ebook download | NCEES-PE study guide | MS-500 dumps pdf | HESI-A2 exam voucher | TCRN book download | DAT practice quiz | Google-PCD official cert guide pdf | Scrum-PSM-II sybex | DEE-1421 nbcot exam prep | NSE7_EFW-6.2 free answers | AFE made easy | ACA-Cloud1 kickass | 1Y0-204 official cert guide library pdf | PEGACSA74V1 book pdf | Servicenow-PR000370 answers | ARA01 kindle | Google-PCSE passing score | PCNSA blueprint | GRE-Quantitative online test | GRE-Verbal passing score | 000-103 training tips | 3I0-012 actual test | 350-401 how many questions | PCCSA study guide | C4040-227 vce download | HPE0-S54 passing skills | ANVE actual test | CPA-AUD passing skills | 300-620 free answers | TEAS-V6 practice test | 350-801 Sample Test | 1D0-520 study | M70-201 visual cert exam | CCSP quiz questions | ITSM20F how many questions | NS0-182 updated questions | MB-220 full version | C9560-517 guaranteed success | CLO-002 practice test | 1D0-541 accurate questions | ABFM sybex | 300-615 ebook download | CLF-C01 questions answers pdf | M2020-229 study island | 350-601 practice questions | LEED-GA free download | 350-701 simulator download | MLS-C01 actualtests | H19-301 questions and answers | 3312 full version | FSLCC official cert guide library pdf | 7130X exam cost | PCNSE-PANOS-9 dump | IIA-CIA-Part1 troytec | 050-6201-ARCHERASC01 exam dumps | DES-1423 official answers | 200-301 testking | ITIL-4-FOUNDATION mock exam | NSE7_EFW-6.0 study material | MA0-107 study guide pdf | 2V0-51-19 updated questions | 3V0-752 study guide | 3V0-732 lab manual | C2150-610 study help | NS0-300 official cert guide library | MB-210 free test engine | CIA-II training videos | AZ-500 lab kit | ML0-320 testking pdf | 010-160 pdf download | QQ0-300 actual test pdf | C2090-317 amazon | CTFL_Syll2018 latest dumps | 700-020 study guide pdf | 9A0-410 blog | MB-230 Sample Question and Answer | C2010-653 pass score | CSWIP pearson vue | 71200X Question Answer Bank | 700-651 book pdf | DEA-41T1 sybex pdf | E20-375 home lab | CSTE material pdf | AACN-CMC pearson vue | HP2-N36 book pdf | 78200X training tips | MB-330 study guide | Google-ACE free e-book | DMV study tools | Google-PCA free book | C2090-616 test prep | EX0-105 case study | MSNCB pdf | C9560-507 questions & answers | ServiceNow-CSA exam tips | 2V0-01-19 sybex | FC0-U61 ebook | DES-3611 exam pdf | APMLE examsokay | XK0-004 Question Bank | JN0-348 lab kit | DP-100 actual test | BCNS-CNS pearson vue | C1000-004 Quiz | NSE8-810 premium vce file | NSCA-CPT download | ANCC-MSN training tools | 000-120 amazon | 700-150 Answers Bank | H12-223 testking | CABA cert guide | 156-115.80 official cert guide | MS-101 passleader | NBDE-I accurate test | ITEC-Massage bootcamp | E20-655 sparknotes | MS-900 online test | FINRA official cert guide pdf | NBRC Sample exam | AWS-CANS vce download | ISEB-PM1 study guide | 700-751 academy | 1D0-610 correct answers | PSM-I free dumps | MB-300 syllabus | DCA is percent of | 156-315-80 Sample Test | 220-1002 q and a questions | NS0-509 test-king | Series-7 Question Bank | ANP-BC exam tips | CPA-REG dump | C2090-101 results | CTAL-TA_Syll2012 exam objectives | CMA Question Bank | CNSC pass4sure dumps | ANCC-CVNC actualtests | P9530-039 syllabus pdf | CAU302 passguide | MB-320 Question Bank | E20-575 questions & answers | 4A0-108 academy | 72200X study guide pdf | C9060-528 download | MB-310 discounted sale | HPE2-W02 objectives | AWS-CSAP download | 220-1001 exam voucher | CWAP-403 Sample exam | 1Y0-A22 questions & answers | CDM Sample Test | 3314 sparknotes | CMS7 exam questions & answers | JN0-1100 simulation questions | PET official cert guide library | 7392X exam collection | PCM testinside | HP2-H65 dumps in pdf | HPE0-J55 sybex | HPE2-K43 examcollection | HP2-Z37 difficulty | HPE2-E71 ebook | NET cert guide | ISTQB-Advanced-Level-3 pass4sure download | 500-470 pearson vue | ATTA simulation questions | AZ-400 accurate questions | HPE0-J57 test questions | PEGAPCSA80V1_2019 camp | C2090-543 new questions | TTA1 Answers Bank | PCCE exam questions & answers | 600-455 online test | 101-01 dumps pdf | CVPM kickass | AZ-900 exam voucher | MD-101 exam success | 99 exam prep | HP2-896 testking pdf | AWS-CSS vce free | ECSS free book | ESPA-EST passing score | CCSPA free questions | ACNP exambraindumps | PCAP-31-02 study island | MD-100 dumps pdf | CCN cert guide | HPE6-A07 certificationking | H12-222 training videos | 500-701 pass4sure download | HDPCD vce files | 300-100 sam learning | 700-105 syllabus | EMT exam voucher | 000-619 downloads | 2V0-01.19 testking | MS-100 online tyari | VACC Question Bank | 7492X tutorial | 1D0-621 certificationking | 500-490 free ebook | 312-50v10 premium vce file | 500-210 exam cost | WPT-R guaranteed success | MK0-201 exam leader | HPE0-J58 exam cram | ITIL-F free pdf | JN0-361 mock | C2090-913 exam dumps | C2150-609 training tools | NBSTSA-CST academy | DEA-64T1 study island | C2090-645 exam answers | 9L0-402 accurate questions | 303-200 answers | CVA download | CLOUDF | LCDC cert guide | APA-CPP study guide | DU0-001 testking pdf | CV0-002 exambraindumps | PT0-001 troytec | CGRN mock exam | 4A0-107 practice test | OG0-021 boot camp | IAHCSMM-CRCST questions & answers | 500-325 cheat sheet pdf | NBDE-II real-exams | FCBA latest dumps | EX0-008 cert guide | PCCN passcertification | CPCE visual cert exam | E20-065 actual test pdf | SCP-500 download | VCS-275 syllabus | NCIDQ Sample Question and Answer | IBCLC Sample Questions | C9550-413 study help | HPE6-A47 frame relay | C2090-320 actual test | C2010-595 how many questions | ITILFND exam guide | C8 dumps | CTAL-TM_Syll2012 recommended book | SDM-2002001030 boot camp | NRA-FPM dumps | 1K0-001 accurate test | TK0-201 boot camp | IFSEA-CFM Sample Test | DES-1721 pdf download | NAPLEX pass tricks | AHIMA-CCS aio testking | SK0-004 q and a questions | 304-200 camp | 700-801 is hard | 312-92 pdf-archive | EC0-232 pearson vue | EC0-350 official cert guide pdf | CBCP elearningexams | 312-38 study island | A00-260 notes | TM12 Sample Test | NCEES-FE accurate test | EX0-001 free download | CDCS-001 actual test | 9A0-411 free ebook | M2070-740 study guide | HCE-5420 exam time | 8002 examsking | MBLEX questions and answers pdf | CHHE blog | 98-368 cert guide | 98-382 Questions Bank | AXELOS-MSP material pdf | AAMA-CMA Sample Question and Answer | CQE free pdf | 4A0-109 prometric exam | NE-BC test-king | CGEIT study tools | ACSM-GEI study guide pdf | 700-551 exam success | HCE-5710 sam learning | 202-450 mock | TEAS-N quick reference | PTCE passcertification | AEMT accurate answers | ISEE pass4sure | CPEA examcollection | ST0-303 difficulty | 7141X network simulator | 156-215-80 correct answers | 500-710 kit | C2010-530 study guide pdf | EC0-479 number of questions | CDL pass tricks | 201-450 premium vce file | GD0-110 accurate questions | CHA test inside | 62-193 questions and answers | 700-901 free book | 500-301 official cert guide library pdf | 7491X exam collection | HPE6-A42 boot camp | 98-383 how many questions | 7765X questions answers pdf | EX0-117 results | 640-692 is hard | 156-915-80 discounted sale | HPE0-J80 pass tips | CPFA premium vce file | 500-551 home lab | PMI-200 lab kit | H12-721 free dumps | HP0-Y50 accurate questions | A00-212 updated questions | CAS-003 exam voucher | HPE0-J78 simulation questions | 4A0-105 mock exam | HP0-P25 Sample Test Questions | C7010-010 discounted sale | IAAP-CAP test prep online | PMBOK-5th sybex pdf | HPE0-S22 book pdf | MA0-102 blueprint | C9530-519 results | C5050-300 Sample Test | A00-240 exam success | CTAL-TTA-001 MCQ | FTCE q and a questions | Firefighter dumps pdf | CMAA sybex | 4A0-100 frame relay | PANCE certkingdom | CWNA-107 training tools | C9550-273 passguide | NCLEX-PN boot camp | HP2-H62 exam tricks | CGAP exam papers | HPE2-Z40 updated questions | 98-381 mock exam | 7220X questions and answers | C9520-427 exam voucher | VCS-322 self test | FSDEV test prep online | BCB-Analyst dump | ACMA-6.4 passing skills | CEMAP-1 answers | 1Y0-371 test questions | CNN academic edition | 250-428 study | ACE simulator download | 9A0-385 pearson vue | VCS-277 pass guarantee | HPE2-T34 pass guarantee | 1D0-61B dumps pdf | HPE6-A43 pass score | 7241X recommended book | NS0-155 full version | 1D0-571 official cert guide | OCN kit | HPE2-K44 notes | HPE2-E55 exam time | HPE2-K42 training tips | CBEST pdf | 301 exam collection | DEV-401 dumps in pdf | 810-440 study guide | CWDP-302 official cert guide pdf | 500-451 lab workbook | PCNSE answers | C9020-662 Questions Bank | 700-265 elearningexams | N10-007 new questions | EX0-007 training tips | HPE0-S52 MCQ | C2090-619 questions answers pdf | HPE2-E69 number of questions | PK0-004 exambraindumps | OAT amazon | CLAD exam prep | S90-01 results | S10-110 vce download | 1Y0-203 pearson vue | 352-001 correct answers | 77-427 dumps pdf | CSQA Question Answer Bank | JN0-411 free dumps | SPHR Quiz | 500-651 discounted sale | H12-261 Quiz | JN0-634 exam questions & answers | TT0-101 exambraindumps | 7230X q and a questions | 98-366 Questions Bank | E20-920 studies | NSE4-5-4 sybex pdf | C2010-555 dumps free download pdf | HP2-B144 exam questions & answers | HPE6-A15 pearson vue | 200-710 pass score | PgMP new topics | GD0-100 Sample Test Questions | T7 vce download | HPE6-A45 Sample Questions | STAAR vce free | 1Y0-240 lab manual | EX0-101 mock | TB0-121 guide | NCBTMB home lab | C2090-312 sybex pdf | C9510-401 official answers | GPHR kickass | S10-210 exam answers | BEC free ebook | FAR study island | PCAT network simulator | NCLEX-RN dumps pdf | HPE0-S51 killtest | C2150-630 dumps pdf | ACMA-6-1 academy | PEGACSSA academic edition | NSE5 lab questions | Series7 real-exams | VCS-257 pdf download | C2090-623 exam cram | HPE2-Z38 exam time | IC3-1 testking pdf | 312-49v9 study guide pdf | E20-385 free download | CPSM1 exam prep | C2150-606 dumps pdf | CSET free test engine | JN0-680 quick reference | 98-367 kaplan test | C2090-552 study help | 312-49v8 actual test | M9510-747 dumps pdf | M2150-810 cheat sheet | HPE2-T22 blog | C2090-930 trainsignal | HPE6-A44 study help | CFA-Level-I Answers Bank | CWAP-402 getfreedumps | CHFP aio downloader | HPE0-J74 study guide | 6210 results | FCESP exam fee | PHR simulator download | Property-and-Casualty latest dumps | HPE2-Z39 pass4sure dumps | A00-281 official cert guide library pdf | MA0-101 sybex pdf | 500-452 full version | SAT official cert guide pdf | OG0-023 training videos | A00-211 study guide | PW0-071 pass4sure | 98-361 actual test pdf | CFP accurate questions | C9530-001 self test | Prince2 Quiz | CSQE | HPE2-E65 training videos | CQIA free dumps | E20-542 kaplan test | RHIA dumps pdf | 9A0-395 official certification guide | HP2-Z34 studies | GE0-807 free dumps | CTFL-001 official answers | 010-111 exam cram | CNA actualtests | FSOT sybex pdf | 250-505 exam engine | NS0-191 troytec | VCS-276 MCQ | GMAT exam cram | EW0-300 free pdf | C9510-418 download | SY0-501 studies | E20-526 exam prep | VCS-323 exam tricks | Misc-Document test questions | EX0-003 recommended book | P3OF actual test pdf | C9060-518 study guide | HPE0-S37 free e-book | H12-211 passguide | TOEFL latest dumps | SSAT syllabus | RCDD-001 pass4sure | IREB book download | HPE6-A41 syllabus | CSCP cheat sheet pdf | P2090-050 questions and answers | 412-79v9 killtest | IELTS study guide | CPSM free pdf | ACT network simulator | MA0-103 pass score | 500-052 exam success | 98-365 pdf download | PSP exam cram | CEH-001 download | H12-221 exam tricks | HPE6-A29 online test | A00-250 exam | 000-039 is percent of | HPE0-J75 trainsignal | HPE0-J76 flashcards pdf | HPE0-J77 network simulator | HPE0-J79 by examtut | IC3-3 exam time | 010-151 exam | HP2-B149 free pdf | PSAT dumps | OG0-091 exam voucher | HP2-B148 quick reference | 156-730 Answers Bank | NSE8 training tools | PGCES-02 cheat sheet pdf | GRE kickass | H12-224 Sample Question and Answer | ADM-211 pass guarantee | ACE001 official cert guide library | ISSMP study material | P9050-005 practice questions | 312-49 discounted sale | CA-Real-Estate network simulator | EX300 official cert guide pdf | TMPTE official certification guide | JN0-346 camp | HPE2-W01 recommended book | HP2-E48 camp | 010-150 latest dumps | RCDD download | HPE2-E67 vce free | ITILSC-OSA official cert guide library | HS330 pass guarantee | HPE0-S46 blueprint | CBAP accurate answers | HD0-100 dump | 150-230 mock | PC0-001 troytec | NCLEX notes | PMI-SP exam questions & answers | 312-76 study guide | HPE2-E68 new topics | H11-851 exam tricks | CITP test inside | CTP sparknotes | 1D0-437 discounted sale | CISM flashcards pdf | CPA-CPP exam papers | P8060-017 number of questions | ISTQB-Advanced-Level-2 practice quiz | A00-280 official cert guide library | CSM-001 official cert guide | PDDM tutorial | M2090-732 Sample Test | DEV-501 full version | NYSTCE cheat sheet | CRRN exam papers | PRINCE2-Practitioner official cert guide library | C2020-605 blog | 98-349 network simulator | ITIL exam collection | CAS-002 self test | E20-555 Sample Test | MTEL killtest | PMI-002 academy | QIA training tools | MCAT new questions | HP2-Z12 number of questions | 000-195 questions answers pdf | GED tutorial | NBCOT exam engine | CWSP-205 syllabus pdf | CFEX exam time | CCBA certification guide | CLEP practice questions | JN0-661 actual test pdf | HP0-M77 answers | Praxis-Core self test | CPFO dumps | AX0-100 vce download | P2065-749 vce free | CAT-440 official answers | CTEL dump | C2090-600 by examtut | EPPP training videos | CTFA | 7893X ebook | ASWB exam engine | F50-533 official cert guide | CISA pass4sure | CSSLP guide | P2070-072 blueprint | ITILF2011 flashcards pdf | MA0-104 passcertification | HP2-N53 testking | EW0-200 exam guide | JN0-1330 correct answers | PMI-ACP exam papers | S90-01A practice quiz | CFSA exam answers | S90-02A test engine | S90-03A mock exam | CRA free answers | CSSBB passguide | 050-730 free e-book | E20-598 pdf download | MA0-100 nbcot exam prep | 9A0-409 test inside | PTCB cheat sheet | PEGACUIS71V1 study | CRISC questions and answers pdf | NCE cert guide | ISSEP passing skills | ICBB vce free | M9560-231 Sample Question and Answer | CAP study guide pdf | OG0-092 vce free | LRP-614 braindump | HAT-680 passcertification | CAPM cheat sheet | HP0-M57 cert guide | CRCM pearson vue | CPIM-BSP exam fee | 000-652 free pdf | CFE | VTNE test prep online | NPTE cert guide | 712-50 correct answers | CPHQ Sample Questions | ASVAB actual test | CEN nbcot exam prep | C9010-262 questions and answers | PMP syllabus pdf | GCIA vce download | C5050-287 blueprint | LSAT exam guide | PEGACSA72V1 best study techniques | GPEN case study | CNOR exam dumps | OG0-093 passleader | CPCM bootcamp | 98-364 guaranteed success | ICGB test engine | GSEC best study techniques | ECDL-ADVANCED study material | QQ0-400 quick reference | CGFNS by examtut | ABV exam time | NSE4 exam leader | HH0-560 actual test pdf | HPE2-T30 bootcamp | 98-375 lab workbook | 000-277 blog | CFRN latest dumps | HD0-300 mock | C5050-285 blog | A30-327 pass4sure download | ADM-201 free book | Series66 best study techniques | CLSSGB answers | 101 Sample exam | CGFM exam leader | ACCP cert guide | CTAL-TA passing score | 4A0-102 free dumps | C2090-424 Answers Bank | Series6 troytec | AND-401 book pdf | C2040-421 elearningexams | CIA-III free pdf | COG-703 notes | CIA-III-2012 guide | HP0-Y52 full version | ACMP accurate questions | CISSP updated questions | HP0-S45 cert guide | ISSAP frame relay | COG-702 sparknotes | RTRP kindle | DANB exam papers | Wonderlic flashcards pdf | CCA-500 pass4sure dumps | SSCP number of questions | ASF questions and answers | 600-460 Sample Test Questions | 412-79 best study techniques | 050-733 exam collection | CAT-140 academic edition | ARDMS test questions | 599-01 vce download | CCRN free ebook | CIA-I study guide pdf | TEAS free dumps | PMI-RMP practice questions | GCFA exam time | GE0-803 study help | M2090-626 Sample Test Questions | M2180-759 Question Bank | C9060-509 online tyari | FPGEE nbcot exam prep | CMQ-OE real-exams | PMI-001 | EX200 Sample Test Questions | GCFW Sample Test | CSSGB free e-book | PEGACPBA71V1 aio downloader | PEGACSA71V1 pdf download | PCNSE7 cheat sheet pdf | ACCUPLACER real-exams | 312-50 exam cram | VMCE_V9 study tools | C9010-022 exam pdf | 301b questions answers pdf | E20-393 sybex pdf | 700-501 troytec | 700-505 cheat sheet | USMLE simulator download | HAT-450 simulation questions | 700-260 dumps free download pdf | CPP cheat sheets | 201 academic edition | P2020-795 testking pdf | HP0-S44 pass guarantee | H13-621 practice questions | PMP-Bundle vce download | QV_Developer_11 official answers | HH0-580 amazon | HP0-S42 questions & answers |

See more dumps on Killexams

A2090-463 | C9550-273 | 312-50v11 | 650-059 | HPE6-A48 | C2030-280 | AND-403 | C2040-421 | MSC-121 | LOT-917 | NailTech | GASF | ISSAP | 000-928 | 310-810 | HS330 | 000-823 | 920-345 | 9A0-411 | H13-621 | 9L0-406 | C2090-913 | P2090-011 | 1T6-511 | RPFT | CIA-III | MLS-C01 | 4H0-020 | MSC-241 | 98-364 | SY0-601 | C2030-284 | 350-501 | C7010-010 | A2030-280 | 2B0-102 | AD0-E104 | C2180-188 | SC0-502 | C2040-421 | NBCC-NCC | 000-752 | FN0-240 | BI0-145 | C8 | A2010-598 | CEMAP-1 | HP2-N48 | 000-M70 | 920-805 |

250-403 Questions and Answers

Pass4sure 250-403 Dumps with Real Questions & Practice Test


QUESTION: 164

Refer to the Exhibit.

image


In the scenario shown, directly assigned to the groups are the following numbers of computers: Southeast Asia - 10, Southwest Asia - 15, Asia - 37, and Headquarters - 120. If security is properly configured and an administrator is assigned management rights to the Southeast Asia group only, how many computers will they see at the world-wide administration level?


  1. 10

  2. 15

  3. 25

  4. 182


Answer: A


QUESTION: 165

Refer to the Exhibit.


image


What should the administrator choose to save a list of computers that can be used in a target?


  1. snapshot

  2. web part


  3. static filter

  4. spreadsheet


Answer: C


QUESTION: 166

Which rule must be followed when configuring a hierarchy?


  1. Each Notification Server must have one parent; each Notification Server must have one child.

  2. Each Notification Server can have zero or one parent; each Notification Server can have zero or more children.

  3. Each Notification Server can have zero or one parent; each Notification Server can have zero or one child.

  4. Each Notification Server can have zero or more parents; each Notification Server can have zero or one child.


Answer: B


QUESTION: 167

Which two Resource Attributes can be inherited from Base Resource Types? (Select two.)


  1. Association Types

  2. Resource Types

  3. Organizational Group

  4. Resource Scope

  5. Data Classes


Answer: A, E


QUESTION: 168

Which service must be configured on all Notification Servers to set up a hierarchy?


  1. Package

  2. OOB

  3. Task

  4. PXE


Answer: A


QUESTION: 169

Refer to the Exhibit.

image


An administrator has cloned the Windows x64 filter and wants to modify it to show unmanaged Windows x64 computers. Given the information provided in the exhibit, which action should the administrator perform to accomplish this task?


  1. in the "{0} Equals section" modify the [vComputerResource].[IsManaged] rule to read 0 instead of 1

  2. in the "{0} Equals section" add a [vComputerResource].[IsManaged] rule to read 0

  3. in the "{0} Equals section" add a [vComputerResource].[UnManaged] rule to read 1

  4. in the "{1} Like section" add an [AeX AC Identification].[System Type] expression of '%unmanaged%


Answer: A


QUESTION: 170

An administrator needs to review several Symantec Management Console reports daily and would like to have them in a single view. How can the reports be combined into a single view?


  1. create a custom dashboard that merges the reports

  2. create a custom portal page that displays each of the reports as web parts

  3. export the reports and import them into one custom folder

  4. link each of the reports to a single custom sub-menu item


Answer: B


QUESTION: 171

Refer to the Exhibit.

image


An administrator has cloned the Daily Event report. What must the administrator change to create a Weekly Event report?


  1. edit the Query Parameters to show a week of data

  2. edit the dateadd(day, -1, @cutoffdate) section

  3. edit the Resolved Query to show a week of data

  4. edit the views on the Views tab


Answer: B


QUESTION: 172

A policy can be applied to which item?


  1. filters

  2. targets

  3. organizational views

  4. organizational groups


Answer: B


QUESTION: 173

Several computer resources displayed within the Active Directory Organizational View were previously removed from Microsoft Active Directory organizational units. An Active Directory import is scheduled to run weekly. Which action can the administrator take to remove these computer resources automatically from the Configuration Management Database (CMDB)?


  1. create and enable an automation policy that removes these computer resources

  2. create a resource filter that contains these computers and delete them all at once from the filter


  3. enable the Directory Synchronization Schedule console option on the Active Directory Import page

  4. create and enable a server task to run a SQL query to remove the computer resources


Answer: C


QUESTION: 174

An IT management company contracts with other companies to manage their IT resources using the Symantec Management Platform. Their revenue is dependent on the number of resources they manage. What should the administrator do so that they will be immediately alerted when a new computer resource is discovered?


  1. create an automation policy based on the "New Computer Discovered" system message

  2. schedule the Update the All Computers Filter task to run every five minutes

  3. schedule the Discovered Computers report to refresh every five minutes

  4. add the administrator's address to the TO_EMAIL parameter in the New Machine automation policy


Answer: A


Symantec 250-403 Exam (Administration of Symantec(TM) Management Platform 7.1) Detailed Information

Train. Certify. Succeed!
Validate technical knowledge and competency by becoming a Symantec Certified Specialist (SCS) based on your specific area of Symantec technology expertise. To achieve this level of certification, candidates must pass one proctored SCS exam based on a combination of Symantec training material, commonly referenced product documentation, and real-world job scenarios.
Certification News
Find out what’s new in the Symantec Certification Program.
Prepare for an Exam
View the list of available exams and see the exam details and recommended preparation for each exam.
Learn about new item types on SCS exams.
Certification Process
Learn about the Certification Testing Process to find out how to register for exams and view exam fees.
Or, register for an exam now.
Certification Documents and Policies
Certification Documents and Policies
Learn about the Symantec Testing Policies and exam security protocols prior to taking your exam.
Manage Your Credentials
Manage Your Credentials
Log in to CertTracker to view exam progress and publish your credentials.
Subject Matter Expert Central
Register for notifications and/or to participate in our certification exam development process. Help design, write, or beta test the next generation of Symantec Certification Exams.
Read some frequently asked questions about Symantec Education Services and find out how to get additional help.
Why Get Certified?
Did you know that Symantec certifications ranked #1 as the top product vendor cyber security certifications by salary in the IT Security Salary Survey (Certification Magazine, November 2015) and that 76% of candidates and recruiters verified that Symantec Certification was discussed as part of the hiring process? Certification can open the door to increased visibility, better opportunities and new jobs in your industry. In today’s highly competitive environment, certification differentiates you as a professional who is serious about applied learning, making you an asset to a prospective employer. Read about the benefits of certification.
Symantec Training
We provide a number of training options to suit your schedule, budget and experience. Online eLearning courses are provided to you at no cost while Virtual Academy and classroom training are provided to you at a reduced cost.
Benefits
Gain a competitive edge
Close more business
Drive larger deals with improved knowledge
Smoother solution deployments
Differentiate yourself from the competition
Satisfy customer needs by selling the right solution
Achieve program membership status with access to more Partner Program benefits
Online eLearning
No cost eLearning that is available online exclusively to Symantec Partner Program members. Earning Symantec accreditations and authorizations may give you access to revenue enhancing and profitability programs. eLearning courses are organized into learning paths that prepare you to successfully complete the Symantec credentials:
Symantec Sales Expert (SSE)
Symantec Sales Expert Plus (SSE+)
Symantec Certified Specialist (SCS)
Virtual Academy
Online learning that recreates the traditional classroom experience via live webcasts, hands-on labs, on-demand modules and expert mentoring. Benefits include:
Less time out of the field
No travel costs
Attend any class in the world
Classroom training
Fee-based technical courses at Symantec locations around the world, offering the same content and in
What is the Symantec Certification Program?
The Symantec Certification Program provides rigorous, objective assessments of Symantec technical expertise through securely proctored, computer-based, multiple-choice exams (based on real-world job tasks). The program validates the skills and technical competencies necessary for Symantec professionals to efficiently implement, administer, and maintain their data protection, high availability, and security environments utilizing Symantec solutions.
Successful completion of the programs’ current requirements will result in the achievement and reward of either a Symantec Certified Specialist (SCS) or Symantec Certified Professional (SCP) certificate.
Who is the audience?
Symantec End Users, Customers, Employees, and Partners (optional). Although each product varies in complexity and depth, all certification exams are created specifically for customers and cover core elements measuring technical knowledge against factors such as installation, configuration, deployment, product management & administration, and day-to-day maintenance. While certification is optional for partners and employees, certification is not a requirement of the Symantec Partner Program and does not count toward program classification.
What is a Symantec Certified Specialist?
An End User, Customer, Employee, and/or Partner who has proven technical knowledge and competency by becoming Symantec certified based on their specific area of expertise with Symantec products.
What is a Symantec Certified Professional?
An End User, Customer, Employee, and/or Partner who has proven technical knowledge and competency by becoming Symantec certified based on their specific solution expertise with multiple Symantec products.
Is the Symantec Certification Program available worldwide?
Yes, it is a global certification program for IT professionals working with Symantec solutions worldwide.
What certifications are currently available?
Symantec offers Symantec Certified Specialist (SCS) and Symantec Certified Professional (SCP) certifications covering several different products and solutions by product versions. See more information on the currently available certifications.
Where can I find the individual certification requirements for each certification?
Certification requirements, sample exams, exam objectives, recommended training and registration is available for each certification and corresponding exam. Please click here for more information on Available Certifications.
What is the benefit of becoming Symantec Certified?
Symantec certified candidates and their companies have the ability to gain industry recognition, competitive differentiation, greater productivity & results, increased user community satisfaction, and a tangible measure of their education investment.
Did you know that 76% of candidates and recruiters verified that Symantec Certification was discussed as part of the hiring process? Certification can open the door to increased visibility, better opportunities and new jobs in your industry. In today’s highly competitive environment, certification differentiates you as a professional who is serious about applied learning, making you an asset to a prospective employer. Read about the benefits of Certification for an Individual and Employer.
Does Symantec End User Certification count toward Partner Program requirements and benefits?
End user certification does NOT count toward Partner Program requirements. To learn more view this FAQ sheet (PDF).
Is my Clearwell certification still valid?
See below for details to learn about the acquisition of Clearwell:
Customers
Partners
Is my PGP certification still valid?
See below for details to learn about the legacy acquisition of PGP:
Customers
Partners
Exams
How and where are the exams administered?
Are exams published on the same schedule worldwide?
How do I register and pay for a Symantec certification exam?
How much does it cost to take an exam?
What is the format of the exams?
How much time is allowed to take an exam?
How will I be notified that I have passed an exam?
How will Symantec be notified that I have passed an exam?
What score must I achieve to pass an exam?
Who sees my exam score(s)?
If I do not pass an exam, can I find out which questions I got wrong?
How many times can I take an exam, is there a waiting period, and is there a cost to retake an exam?
How can I find out what topics an exam will cover?
Are the exams based on current Symantec product versions?
How do I know what software release version an exam covers?
Are practice or sample exams available?
Why does Symantec list a range of questions for exams?
How are the exams developed?
How are passing scores established?
Certification
Training and Education
The exams are computer-based and delivered at Pearson VUE testing centers. Pearson VUE provides computer-based testing for information technology, academic, government and professional testing programs around the world. Pearson VUE provides a full suite of services from test development to data management, and delivers exams through the world’s most comprehensive and secure network of Test Center Locations in 175 countries. Pearson VUE is a business of Pearson (NYSE: PSO; LSE: PSON), the international media company, whose businesses include the Financial Times Group, Pearson Education and the Penguin Group.
Are exams published on the same schedule worldwide?
Exams will be available on the same schedule worldwide in English at Pearson VUE. Translations will be determined on a country-by-country basis.
How do I register and pay for a Symantec certification exam?
To register for a Symantec certification exam, login or create a Symantec CertTracker account. Exam fees are payable by credit card or by voucher. View the step-by-step instructions on how to register.
View the step-by-step instructions on how to purchase exam vouchers.
How much does it cost to take an exam?
The fee for a standard released Certification exam is $225 USD (or your country’s currency equivalent).
Symantec reserves the right to change exam fees at any time. Always check Pearson’s website to verify exams costs, schedules, and locations.
What is the format of the exams?
Exams are delivered in multiple-choice format, with each having approximately 65-100 questions. It’s common for the exams to contain exhibits/graphics. Exhibits/graphics are shown directly above the question.
How much time is allowed to take an exam?
Allotted exam time varies by exam length. It typically takes one minute to complete each exam question.
How will I be notified that I have passed an exam?
Pearson VUE provides you with instant results at the completion of your exam. A score report will be printed and given to you before you leave the testing center. Candidates are also able to view exam progress by logging into CertTracker.
How will Symantec be notified that I have passed an exam?
Symantec receives candidate exam results daily via file transfers from Pearson VUE to CertTracker Be sure you keep your personal information in your CertTracker profile up-to-date so that you receive proper credit for exams passed and certifications earned.
What score must I achieve to pass an exam?
Passing scores vary by exam. For more information on specific certifications in each category, please see the certification exam details within your selected product solution training path.
Who sees my exam score(s)?
You, Symantec, and your company (if you designate).
If I do not pass an exam, can I find out which questions I got wrong?
No. Symantec maintains this policy to ensure security over the exam questions.
How many times can I take an exam, is there a waiting period, and is there a cost to retake an exam?
If you do not pass an exam on your first attempt, you must wait at least 3 days (72 hours) before a second attempt. If you do not pass an exam on your second attempt, then you must wait at least 2 weeks (14 days) between each additional attempt. If you need to retake an exam that you have already passed in order to fulfill a certification track requirement, you may do so after 3 months. The same cost applies whether you take an exam once or many times.
How can I find out what topics an exam will cover?
Certification requirements, sample exams, exam objectives, recommended training and registration is available for each certification and corresponding exam. For more information on specific certifications in each category, please see the certification exam details within your selected product solution training path.
Are the exams based on current Symantec product versions?
Exams are developed for the current version of the Symantec product release at the time of development. Exams may be updated after significant new versions are released. New exams may not always correspond to the software release schedule.
How do I know what software release version an exam covers?
For more information on specific certifications in each category, please see the certification exam details within your selected product solution training path.
Are practice or sample exams available?
Sample exams are available. Each sample exam consists of multiple-choice items. Some items may have a supporting exhibit which you will be directed to view before answering the item. The sample exams are not timed, however, you should attempt to complete them as quickly as you can. Certification requirements, sample exams, exam objectives, study guides, recommended training, and registration is available for each certification and corresponding exam. For more information on specific certifications in each category, please see the certification exam details within your selected product solution training path.
Why does Symantec list a range of questions for exams?
Symantec regularly conducts statistical analyses of certification exam results for exam maintenance purposes. In doing so, Symantec publishes a range of questions per exam to account for “unscored” questions. In order to ensure the value of the Symantec certification program, Symantec routinely updates exams with new questions on an unannounced basis. Those new questions are initially delivered as “unscored” so that Symantec can evaluate the performance in the field/on the released exam. The “unscored” questions do not count towards your passing score and additional time is already incorporated into the total exam duration to answer these questions.
Symantec also regularly updates exam questions where the actual number of questions per exam may vary from time to time as these unannounced updates occur.
How are the exams developed?
Symantec end users, both internally and in the field, are studied to define the job performance requirements. The results determine the minimum level of competence required for the defined job performance and is tested in the exams. Symantec follows industry standards for “high stakes” exam development.
How are passing scores established?
Although it is intuitive to think that an appropriate passing score for an examination should be 70 or 75 percent correct based on personal experiences taking classroom tests, these arbitrary values may not reflect the performance level expected of the “minimally qualified candidate” given the difficulty of the test. For example, if the examination is very easy, a passing score of 70 may be too low. However, if the examination is very difficult, this same value may be too high.
Establishing passing scores requires the application of systematic procedures that consider the defined performance level definition of the “minimally qualified candidate” and the difficulty of the examination. Before the final passing scores are established, they are evaluated to ensure that the available validity evidence supports their use for the intended purpose of distinguishing the “minimally qualified candidates” from those who are not yet qualified. This systematic method is used to establish and maintain the fairness, validity and reliability of exams.
In order to ensure the value of the Symantec certification program, Symantec routinely updates exams with new questions. In these cases the passing percentage could change per exam from time to time as these unannounced updates occur
250-403 Administration of Symantec(TM)(R) Management Platform 7.1 Study Guide Prepared by Killexams.com Symantec Dumps Experts Exam Questions Updated On : Click To Check Update Killexams.com 250-403 Dumps | Real Questions 2019 100% Real Questions - Memorize Questions and Answers - 100% Guaranteed Success Free Download Link : https://killexams.com/demo-download/250-403.pdf 250-403 exam Dumps Source : Download 100% Free 250-403 Dumps PDF Test Code : 250-403 Test Name : Administration of Symantec(TM)(R) Management Platform 7.1 Vendor Name : Symantec Q&A : 174 Real Questions Read 250-403 dumps with real question to pass your exam We provide 250-403 exam questions with 100% pass guarantee. You have to practice questions for atleast 24 hours to obtain best scores in the exam. Your actual task to pass in 250-403 exam, begins with killexams.com 250-403 exam practice questions. All 250-403 dumps updated and validated on regular basis. If you are interested in just Passing the Symantec 250-403 exam to get a high paying job, you need to visit killexams.com and register to download full 250-403 question bank. There are several specialists working to collect 250-403 real exam questions at killexams.com. You will get Administration of Symantec(TM)(R) Management Platform 7.1 exam questions and VCE exam simulator to make sure you pass 250-403 exam. You will be able to download updated and valid 250-403 exam questions each time you login to your account. There are several companies out there, that offer 250-403 dumps but valid and updated 250-403 question bank is not free of cost. Think twice before you trust on Free 250-403 Dumps provided on internet. It require you to clear your concepts about all main concepts and objectives to Pass Symantec 250-403 exam. Just reading 250-403 course book is not sufficient. You need to learn about tricky scenarios and questions asked in real 250-403 exam. You need to go to killexams.com and download Free 250-403 PDF sample questions and read. If you feel that you can understand those 250-403 questions, you should register to download complete 250-403 question bank at very attractive discount coupons. That will be your first step toward success in Administration of Symantec(TM)(R) Management Platform 7.1 exam. Download and install 250-403 VCE exam simulator in your computer. Memorize 250-403 dumps and take practice test frequently with VCE exam simulator. When you feel that you are ready for real 250-403 exam, go to test center and register for actual test. You can copy 250-403 dumps PDF at any device line ipad, iphone, laptop, smart tv, android device to read and memorize the 250-403 braindumps while you are on vacation or travelling. This will save lot of your time, you will get more time to study 250-403 real questions. Practice 250-403 dumps with VCE exam simulator again and again until you get 100% marks. When you feel confident, straight go to test center for real 250-403 exam. Features of Killexams 250-403 dumps -> Instant 250-403 Dumps download Access -> Comprehensive 250-403 Questions and Answers -> 98% Success Rate of 250-403 Exam -> Guaranteed Real 250-403 exam Questions -> 250-403 Questions Updated on Regular basis. -> Valid 250-403 Exam Dumps -> 100% Portable 250-403 Exam Files -> Full featured 250-403 VCE Exam Simulator -> Unlimited 250-403 Exam Download Access -> Great Discount Coupons -> 100% Secured Download Account -> 100% Confidentiality Ensured -> 100% Success Guarantee -> 100% Free Dumps Questions for evaluation -> No Hidden Cost -> No Monthly Charges -> No Automatic Account Renewal -> 250-403 Exam Update Intimation by Email -> Free Technical Support Exam Detail at : https://killexams.com/pass4sure/exam-detail/250-403 Pricing Details at : https://killexams.com/exam-price-comparison/250-403 See Complete List : https://killexams.com/vendors-exam-list Discount Coupon on Full 250-403 Dumps Question Bank; WC2017: 60% Flat Discount on each exam PROF17: 10% Further Discount on Value Greatr than $69 DEAL17: 15% Further Discount on Value Greater than $99 250-403 Customer Reviews and Testimonials 250-403 exam prep had been given to be this smooth. HI, I had sign up for 250-403. Though I had study all chapters intensive, however your question bank supplied enough training. I passed this exam with 99 % the yesterday, Thanks lots for to the point question bank. Even my doubts were clarified in minimum time. I desire to use your carrier in future as correctly. You men are doing a top notch process. Thanks and Regards. Concerned for 250-403 exam? Get this 250-403 question . My friends told me I could count on killexams.com for 250-403 exam preparation, and this time I did. The brain dumps are very convenient to use, I love how they are set up. The question order helps you memorize things better. I passed with 89% marks. Passing the 250-403 exam with enough understanding. The Dumps provided with the help of the killexams.com became some thing Great. just 76% is sufficient for the exam, but I secured 92% marks within the real 250-403 exam. All credit score goes to you. tough to imagine that if I used every other product for my exam. Its tough to get an super product like this ever. thanks for the whole thing you supplied to me. I am able to sincerely recommend it to all. Got no trouble! three days schooling 250-403 real exam questions is required. In order to study and prepare for my 250-403 exam, I used killexams.com braindumps and exam simulator. All thanks to this incredibly astounding killexams.com. Thank you for assisting me in passing my 250-403 exam. Real 250-403 questions! I was not expecting such ease in exam. I handed 250-403 exam. I assume 250-403 certification is not given enough publicity and PR, given that its virtually well however seems to be below rated these days. That is why there arent many 250-403 braindumps with out price, so I had to buy this one. killexams.com package grew to turn out to be out to be as super as I expected, and it gave me precisely what I needed to recognise, no deceptive or wrong information. Awesome enjoy, excessive five to the team of builders. You men rock. Administration of Symantec(TM)(R) Management Platform 7.1 exam Whilst it is very hard task to choose reliable exam questions / answers resources regarding review, reputation and validity because people get ripoff due to choosing incorrect service. Killexams. com make it certain to provide its clients far better to their resources with respect to exam dumps update and validity. Most of other peoples ripoff report complaint clients come to us for the brain dumps and pass their exams enjoyably and easily. We never compromise on our review, reputation and quality because killexams review, killexams reputation and killexams client self confidence is important to all of us. Specially we manage killexams.com review, killexams.com reputation, killexams.com ripoff report complaint, killexams.com trust, killexams.com validity, killexams.com report and killexams.com scam. If perhaps you see any bogus report posted by our competitor with the name killexams ripoff report complaint internet, killexams.com ripoff report, killexams.com scam, killexams.com complaint or something like this, just keep in mind that there are always bad people damaging reputation of good services due to their benefits. There are a large number of satisfied customers that pass their exams using killexams.com brain dumps, killexams PDF questions, killexams practice questions, killexams exam simulator. Visit Killexams.com, our test questions and sample brain dumps, our exam simulator and you will definitely know that killexams.com is the best brain dumps site. COG-632 examcollection | 156-915 practice questions | GED questions and answers | HP0-621 sample test | SK0-004 exam questions | 000-896 practice exam | P2090-046 questions and answers | CUR-009 mock exam | 2B0-019 test prep | 650-322 brain dumps | HP2-E47 practice test | 70-743 Practice Test | 000-M97 free pdf | HP2-E50 real questions | PANRE VCE | C2040-442 braindumps | 000-376 test prep | A2040-404 practice questions | HP3-C11 study guide | BH0-010 real questions | 000-711 braindumps | 920-806 exam prep | 132-S-900.7 free pdf | LOT-801 free pdf download | NSE4_FGT-6-0 real questions | 9A0-066 questions answers | 117-102 practice test | ST0-079 real questions | HP2-T29 braindumps | C2090-632 sample test | VCS-276 practice exam | MD0-251 practice test | 000-656 dump | HP2-K10 Practice test | 1Z0-475 exam prep | 1Z0-853 brain dumps | PEGACSA72V1 study guide | CRNE questions and answers | 9A0-314 test prep | NSE5 pdf download | View Complete list of Killexams.com Brain dumps 000-874 practice questions | HP2-E28 questions answers | 1Z0-971 test prep | 1T6-510 cheat sheets | 70-486 dumps | 000-101 pdf download | 9L0-623 real questions | M9560-760 mock exam | HP2-K35 questions and answers | 000-M87 braindumps | PEGACBA001 braindumps | HP0-Y24 free pdf | HP2-061 brain dumps | 920-482 free pdf | EW0-100 study guide | 251-351 practice test | HP2-N57 questions and answers | 1Z0-950 Practice test | 1Y0-240 braindumps | HP0-Y52 examcollection | Administration of Symantec(TM)(R) Management Platform 7.1 test Prometic reports fourth quarter and 2018 year-end financial results | killexams.com 250-403 Real Questions and VCE Practice Test Total revenues for 2018 of $47.4 million compared to $39.1 million in 2017 Significant increase in bioseparation 2018 revenues to $22.7 million, a 35% increase over 2017 Net loss of $ 237.9 million for the year ended December 31, 2018 includes a non-cash writedown of intangible assets related to IVIG of $ 150.0 million Near-term financing shortfall requires urgent action to restructure the Corporation's indebtedness and raise capital LAVAL, QC, April 1, 2019 /PRNewswire/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) (Prometic or the Corporation) reported today its financial results for the fourth quarter and year-ended December 31, 2018. 2018 Fourth Quarter and Year-End Financial Results RevenuesTotal revenues for the year ended December 31, 2018 were $47.4 million compared to $39.1 million during the comparative period of 2017, which represents an increase of $8.3 million. Total revenues for the quarter ended December 31, 2018 were $10.6 million compared to $6.6 million during the comparative period of 2017, representing an increase of $4.0 million. Revenues from the sale of goods were $45.6 million during the year ended December 31, 2018 compared to $16.5 million during the corresponding period of 2017, representing an increase of $29.1 million. The increased sales revenues for 2018 were mainly due to $22.8 million in sales of normal source plasma. The Corporation decided to sell this inventory as a result of the change in the production forecast due to the delay of the Biologics License Application ("BLA") approval for Ryplazim (plasminogen), ("RyplazimTM"). The remainder of the increase is mainly due to an increase in third party sales in the Bioseparations segment of $5.9 million. Revenues from the sale of goods were $10.3 million during the fourth quarter of 2018 compared to $5.5 million during the corresponding period of 2017, representing an increase of $4.8 million which was due to sales of $3.1 million of normal source plasma and an increase in third party bioseparations sales of $1.7 million. Cost of sales and other production expensesCost of sales and production were $38.0 million during the year ended December 31, 2018 compared to $10.1 million for the corresponding period in 2017, representing an increase of $27.9 million. Cost of sales and production for the quarter ended December 31, 2018 were $7.6 million compared to $2.4 million for the corresponding period in 2017, representing an increase of $5.2 million. The majority of the increase is due to the sales of normal source plasma in 2018 which overall was sold slightly below its carrying amount on a cumulative basis for the year but at a slight profit during the fourth quarter of 2018. The remainder of the increase in both periods is explained by the increase in products sold by the Bioseparations segment. Research and Development ("R&D")R&D expenses were $91.7 million during the year ended December 31, 2018 compared to $100.4 million for the corresponding period in 2017, representing a decrease of $8.7 million. R&D expenses were $21.1 million during the quarter ended December 31, 2018 compared to $28.2 million for the corresponding period in 2017, representing a decrease of $7.1 million. R&D expenses include the manufacturing cost of plasma-derived and small molecule therapeutics to be used in clinical trials and for the development of our production processes, with the majority of R&D expenses incurred in the plasma-derived therapeutics segment. The manufacturing cost of plasma-derived and small molecule therapeutics was $38.6 million during the year ended December 31, 2018 compared to $34.7 million during the year ended December 31, 2017, representing an increase of $3.9 million. The manufacturing cost of plasma-derived and small molecule therapeutics to be used in clinical trials and for the development of our production processes was $10.5 million during the three months ended December 31, 2018 compared to $10.9 million during the corresponding period of 2017, representing a decrease of $0.5 million. In 2018, there was a reduction in production activities at the Laval manufacturing plant while the facility focused on addressing the comments received by the U.S. Food and Drug Administration ("FDA") following their audit of this facility as part of the review of the BLA for RyplazimTM. This resulted in a reduction in overall manufacturing expenses for Plasma-derived therapeutics. However since there was no commercial production in 2018, none of these expenses were capitalized to inventories as compared to 2017. Other R&D expenses were $53.0 million during the year ended December 31, 2018 compared to $65.7 million for the corresponding period in 2017, representing a decrease of $12.6 million, and $10.7 million during the quarter ended December 31, 2018 compared to $17.3 million for the corresponding period in 2017, representing a decrease of $6.6 million. The decrease in the clinical trial and pre-clinical research expenses in both the small molecules and plasma-derived therapeutics segments were partially offset by additional spending in relation to the implementation and validation of additional analytical assays and "in-process" controls in the manufacturing of Ryplazim. Story continues Administration, Sales & MarketingAdministration, selling and marketing expenses were $31.5 million during the year ended December 31, 2018 compared to $31.4 million for the corresponding period in 2017, representing an increase of $0.1 million. The increase is mainly due to the increase in severance compensation which was partially offset by a decline in marketing expense. Administration, selling and marketing expenses were $10.7 million during the quarter ended December 31, 2018 compared to $8.8 million for the corresponding period in 2017, representing an increase of $1.9 million. The increase is mainly due to the increase in severance compensation. Finance CostsFinance costs were $22.1 million for the year ended December 31, 2018 compared to $8.0 million during the corresponding period of 2017, representing an increase of $14.1 million. Finance costs were $6.6 million for the quarter ended December 31, 2018 compared to $2.6 million during the corresponding period of 2017, representing an increase of $3.9 million. This increase reflects the higher level of debt during the year ended December 31, 2018 compared to the same period of 2017. Gain on extinguisment of LiabilitesOn November 14, 2018, the Corporation and Structured Alpha LP ("SALP"), an affiliate of Thomvest, modified the terms of the four loan agreements to extend, subject to compliance with covenants and debt servicing obligations, the maturity date of the non-revolving credit facility ("Credit Facility") from November 30, 2019 to September 30, 2024 and all three original issue discount notes from July 31, 2022 to September 30, 2024. The debt modification was accounted for as an extinguishment of the previous loans and the recording of new loans at their fair value determined as of the date of the modification, resulting in the recording of a gain on extinguishment of liabilities of $34.9 million Impairment losses on Intravenous Immunoglobulin ("IVIG") AssetsAs a result of various events affecting the Corporation during 2018, including; 1) the delay of the commercial launch of Ryplazim following the identification by the FDA of a number of changes required in the Chemistry, Manufacturing and Controls ("CMC") section of the BLA submission for congenital plasminogen deficiency, 2) the Corporation's limited financial resources since Q4 2018, which significantly delayed manufacturing expansion plans and resulted in the Corporation focusing its resources on refiling the RyplazimTM BLA as soon as possible; 3) the recognition of the larger than anticipated commercial opportunities for RyplazimTM, and 4) the change in executive leadership in Q4, the Corporation modified its strategic plans in Q4 to focus all available plasma-derived therapeutic segment resources on the manufacturing and development of RyplazimTM, for the treatment of congenital plasminogen deficiency and other indications. This, combined with the significant work determined to be required on the CMC section of an IVIG BLA, has caused the Corporation to suspend any new activities on IVIG. These changes and their various impacts prompted management to perform an impairment test of the intangible assets related to IVIG. Cash inflows beginning beyond 2023 were not considered in the calculation of the value in use impairment test due to the inherent uncertainty in forecasting cash flows beyond a five year period. As a result, Impairment losses totalling $150.0 million were recorded on these assets for the year and fourth quarter ended December 31, 2018. Net LossThe Corporation incurred a net loss of $237.9 million during the year ended December 31, 2018 compared to a net loss of $120.0 million for the corresponding period of 2017, representing an increase in the net loss of $117.9 million. The net loss in 2018 is higher mainly due to the non-cash impairment losses of $150.0 million related to IVIG, and the increase in finance cost of $14.1 million in the year ended December 31, 2018 compared to the corresponding period of 2017. This was partially offset by the recognition of a gain on extinguishments of liabilities of $33.6 million during the year ended December 31, 2018 compared to a loss on extinguishment of liabilities of $4.2 million for the corresponding period in 2017. Offsetting the increase in loss was the fact that no bad debt expense was recorded in 2018 while a $20.5 million expense was recorded in the previous year. The Corporation incurred a net loss of $141.3 million during the quarter ended December 31, 2018 compared to a net loss of $41.6 million for the corresponding period of 2017, representing an increase in net loss of $99.7 million. The increase was mainly affected by the impairment losses of $150.0 million related to IVIG recorded during the quarter ended December 31, 2018. This was partially offset by the recognition of a gain on extinguishment of liabilities of $33.6 million during the year ended December 31, 2018 compared to a loss on extinguishment of liabilities of $4.2 million for the corresponding period in 2017. Offsetting the increase in loss was the fact that no bad debt expense was recorded in 2018 while a $20.5 million expense was recorded during the fourth quarter of 2017. Commenting on the fourth quarter and 2018 year-end financial results, Bruce Pritchard, Prometic's Chief Operating Officer and Chief Financial Officer, said, "We have delivered on the financial guidance provided for 2018 with significantly reduced expenses and cash flows used in operating activities and increasing product sales. This allowed us to extend our cash runway into early 2019. We extended the repayment terms of our debt to 2024, subject to compliance with our covenants and debt service obligations, and implemented an at-the-market ("ATM") equity distribution program to help provide short term operating funds. We also retained the services of a global financial advisory and asset management firm to help us raise non-dilutive capital from partnerships and monetization of non-core assets. However, cash remains limited and we continue to rely on the support of SALP while working on these other initiatives." "Addressing our material liquidity and balance sheet challenges remains our highest priority. We anticipate that it will most likely require a combination of material corporate, financial and business development transactions to successfully stabilize the financial and liquidity position. This could include a restructuring of the SALP debt and / or recapitalization transaction, and a significant additional equity financing to finance the Corporation to value-creation catalysts such as partnerships and monetization of non-core assets " added Mr. Pritchard. Small Molecule Therapeutics Segment Key Events for 2018: PBI-4050 Published papers on the novel anti-fibrotic mechanism of action of its small molecule lead drug candidate, PBI-4050, in the American Journal of Pathology, in the Journal of Clinical Investigation and in the Journal of Pharmacology and Experimental Therapeutics PBI-4050 Disclosed new clinical data from the ongoing Alstrm Syndrome ("AS") phase 2 open label clinical trial being conducted in the U.K. demonstrating that the clinical activity and tolerability of PBI-4050 were sustained with prolonged treatment with further clinical activity in the heart and liver observed with longer treatment exposure PBI-4050 Received a Rare Pediatric Disease designation from the FDA for the treatment of AS 2019 Updates: Following the completion of the review and prioritization of all programs and assets, the main priorities for the small molecule therapeutics segment are: PBI-4050 The filing and approval of an Investigational New Drug application to enable the commencement of the pivotal phase 3 clinical study of PBI-4050 in AS during H2 2019. PBI-4050 - Prometic is planning a randomized, placebo-controlled phase 2 clinical study of PBI-4050 in patients with Nonalcoholic steatohepatitis ("NASH") to be initiated before the end of 2019 following successful financing PBI-4050 Prometic is planning a randomized, placebo-controlled, phase 2b clinical study of PBI-4050 in patients with idiopathic pulmonary fibrosis ("IPF") before the end of 2019 following successful financing. PBI-4547 Prometic is planning a phase 1 clinical study for its next small molecule compound, PBI-4547. This study is also expected to commence before the end of 2019 following successful financing. Plasma-Derived Therapeutics Segment Key Events for 2018: RyplazimTM Received a Complete Response Letter ("CRL") from the FDA arising from its review of the RyplazimTM BLA. The FDA identified the need for Prometic to make a number of changes in the Chemistry, Manufacturing and Controls ("CMC") portion of its BLA filing requiring the implementation and validation of additional analytical assays and "in-process controls" in the manufacturing process of Ryplazim. RyplazimTM Completed a Type C meeting with the FDA to discuss the Company's proposed action plan for the implementation of additional analytical assays and in-process controls related to the RyplazimTM manufacturing process. IVIG Presented new clinical data from the Corporation's pivotal phase 3 clinical study at the Clinical Immunology Society annual meeting in Toronto. The clinical data presented demonstrated comparable safety and efficacy data to existing commercial IVIG products without any significant drug related safety issues. Both clinical primary and secondary endpoints in adult patients suffering from primary immunodeficiencies were met and achieved. 2019 Updates: Following the completion of the review and prioritization of all programs and assets, the main priorities for the plasma-derived therapeutics segment are RyplazimTM The corporation expects to refile the BLA for Ryplazim during H2- 2019. After acceptance of the BLA, FDA would establish a new PDUFA date which the Corporation still believes would be eligible for a priority review. RyplazimTM The Corporation has determined that the best course of action would be to seek third party partners to assist in the commercialization of Ryplazim for all global markets, and discussions are currently ongoing to establish such arrangements. IVIG Prometic has now completed the required clinical package for IVIG required for a future BLA submission to the FDA. The completion of a robust CMC package for IVIG prior to filing a BLA still requires substantial work, time and investment. The Corporation needs to prioritize manufacturing capacity planning to meet the volume demands for RyplazimTM. IVIG and selected further proteins remain in our pipeline. However, the advanced stage of development and economics of RyplazimTM support a compelling case to focus all the available resources of the plasma-derived therapeutics segment on this therapeutic family to optimize its launch and growth. This, combined with the significant work determined to be required on the CMC section of an IVIG BLA, caused the Corporation to suspend any new activities on IVIG. This will result in a material delay to the commercialization of IVIG as compared to previous timelines and as such, $150.0 million of impairments on the assets pertaining to IVIG activiteswas recorded. Bioseparations Segment Key Events for 2018: External sales for 2018 exceeded $22.7 million, which represents a 35% increase over 2017. The Corporation anticipates moderate revenue growth for 2019 due to a number of factors including, the expansion of manufacturing activities by existing clients who utilize Prometic's products in their production processes, the adoption of products by new clients, and the introduction of new products in the bioseparation market. 2019 Update: The ongoing manufacturing expansion of the Isle of Man facility will enable the company to manufacture over 35,000 litres of chromatography adsorbents annually, with a potential sales value exceeding $133 million per annum. This additional manufacturing capacity will be used to meet the growing demand for the segment's products, and to provide the resins required for Prometic's own PPPSTM plasma protein manufacturing operations. Corporate and Operational Update Key Events for 2018: Subject to compliance with applicable covenants and servicing obligations, extended the maturity dates of its US$80 million (approx. $100 million) Credit Facility and original issue discount notes to September 2024 with SALP. Provided a corporate update related to a series of initiatives aiming at lengthening the cash runway to better position the Corporation to achieve its objectives. These included a significant reduction in the Corporation's cash used in operations for 2019, driven in part by growth in its bioseparation revenues and by a reduction of anticipated R&D expenditures by up to $30 million. Announced the closing of an ATM equity distribution agreement with Canaccord Genuity Corp. The ATM allows the Corporation, at its sole discretion and subject to conditions set forth in the equity distribution agreement, to issue small tranches of common shares from treasury, at prevailing prices and in appropriate market conditions. Named Prof. Simon Best as Interim Chief Executive Officer. Prof. Best has served as the Chairman of the Prometic Board of Directors since May 2014 and has over 30 years of global life sciences expertise with a focus on business development, strategic planning and product commercialization. Prof. Best succeeded Mr. Pierre Laurin who stepped down from his management and board responsibilities in December 2018. Subsequent Events to Fourth Quarter and 2018 Year-End Management and the Board of Directors are engaged in a comprehensive strategy to improve the financial and business conditions of the Corporation and, in January 2019, commenced a process to explore and evaluate potential strategic alternatives focused on maximizing shareholder value, including potential acquisitions, joint ventures, strategic alliances, or other merger and acquisition or capital markets transactions as well as any other transaction or alternative available to the Corporation. Concurrently, management and the Board of Directors have been actively exploring opportunities to bring forward cash flows to repay debt and fund working capital requirements. In conjunction with the strategic review and liquidity issues faced by the Corporation, in February 2019, the Board of Directors formed a special committee of independent directors to oversee the strategic review process (the "Special Committee"). The Special Committee meets regulary and oversees the work of management and the Corporation's financial and legal advisors in respect of such mandate. In February 2019, the Corporation engaged Lazard, a global financial advisory and asset management firm, to review and execute key strategic transactions focused on maximizing shareholder value. These transactions could include, among other things, the out-licensing of drug candidates and monetization of non-core assets.The Corporation has not set a timetable for this process, and there can be no assurance that a transaction will be entered into or consummated, or, if a transaction is undertaken, as to its terms, structure or timing. The Corporation does not expect to make further public comment regarding these matters unless and until the Board has approved a specific transaction or has concluded its review of strategic alternatives. In February and March 2019, the Corporation secured two additional tranches for a total of US$15.0 million from SALP under the existing Credit Facility. Concurrently, 19,401,832 warrants exercisable for Series A Preferred Shares of the Corporation with a term of eight years and an exercise price of $0.156 per warrant were issued on February 22, 2019. The Corporation drew US$10.0 million ($13.2 million) and US$5.0 million ($6.7 million) on February 22 and March 22 2019, respectively. During the first quarter of 2019, the Corporation issued 12,870,600 common shares under the ATM for total cash proceeds of $4.1 million. On March 31, 2019, Ms. Kory Sorenson resigned from Prometic's Board of Directors. Conference Call Information Prometic will host a conference call at 11:00 am (ET) on Tuesday April 2, 2019. The telephone numbers to access the conference call are (647) 427-7450 and 1-888-231-8191 (toll-free). A replay of the call will be available as of Tuesday April 2, 2019 at 2:00 pm. The numbers to access the replay are 1-416-849-0833 and 1-855-859-2056 (passcode:3198209). A live audio webcast of the conference call, with slides, will be available through the following : https://event.on24.com/wcc/r/1969851/0D5A0C85F48EBF7260AFC1BE9877F748 Additional Information in Respect to the Fourth Quarter and Year Ended December 31, 2018 Prometic's MD&A and 2018 consolidated financial statements for the quarter and year ended December 31, 2018 will be filed on SEDAR (http://www.sedar.com) and will be available on the Company's website at www.prometic.com. Prometic has decided to use the "notice-and-access" mechanism for delivery of its materials to its shareholders. Under the Notice-and-Access model, instead of receiving printed copies of Prometic's Audited Consolidated Financial Statements for the year ended December 31, 2018 and Management's Discussion and Analysis for the year-ended December 31, 2018 (collectively, the "Annual Report"), shareholders are invited to consult the Annual Report on Prometic's website at www.prometic.com under investors & media/investor briefcase, or on SEDAR's website. A copy of the Annual Report will also be available upon request, by telephone at 1-888-959-4007 or online at www.prometic.com/contactus. About Prometic Life Sciences Inc. Prometic (www.prometic.com) is a biopharmaceutical corporation with two drug discovery platforms focusing on unmet medical needs. The first platform (small molecule therapeutics) stems from the discovery of two receptors which we believe are at the core of how the body heals: namely, promoting tissue regeneration and scar resolution as opposed to fibrosis. One of the lead drug candidates emerging from this platform, PBI-4050, is expected to enter pivotal phase 3 clinical trials for the treatment of Alstrm syndrome. The second drug discovery and development platform (plasma-derived therapeutics) leverages Prometic's experience in bioseparation technologies used to isolate and purify biopharmaceuticals from human plasma. The Corporation's primary goal with respect to this second platform is to address unmet medical needs with therapeutic proteins not currently commercially available, such as Ryplazim.The Corporation also provides access to its proprietary bioseparation technologies to enable pharmaceutical companies in their production of non-competing biopharmaceuticals. Recognized as a bioseparations expert, the Corporation derives revenue from this activity through sales of affinity chromatography media which contributes to offset the costs of its own R&D investments. We are headquartered in Laval, Quebec (Canada) with R&D facilities in Canada, the United Kingdom and the United States, manufacturing facilities in Canada and the Isle of Man and corporate and business development activities in Canada, the United States, Europe and Asia. Forward Looking Statements This press release contains forward-looking statements about Prometic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Prometic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Prometic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Prometic's Annual Information Form for the year ended December 31, 2018, under the heading "Risk and Uncertainties related to Prometic's business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise. View original content:http://www.prnewswire.com/news-releases/prometic-reports-fourth-quarter-and-2018-year-end-financial-results-300822305.html 10-Q: QUICKLOGIC CORPORATION | killexams.com 250-403 Real Questions and VCE Practice Test (EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following Management's Discussion and Analysis of Financial Condition and Results of Operations, as well as information contained in "Risk Factors" in Part II, Item 1A and elsewhere in this Quarterly Report on Form 10-Q, contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend that these forward-looking statements be subject to the safe harbor created by those provisions. Forward-looking statements are generally written in the future tense and/or are preceded by words such as "will," "may," "should," "forecast," "could," "expect," "suggest," "believe," "anticipate," "intend," "plan," or other similar words. Forward-looking statements include statements regarding our strategies as well as (1) our revenue levels, including the commercial success of our Customer Specific Standard Products, or CSSPs, and new products, (2) the conversion of our design opportunities into revenue, (3) our liquidity, (4) our research and development efforts, (5) our gross profit and factors that affect gross profit, (6) our level of operating expenses, (7) our partners and suppliers and (8) industry trends. The following discussion should be read in conjunction with the attached condensed unaudited consolidated financial statements and notes thereto, and with our audited consolidated financial statements and notes thereto for the fiscal year ended December 30, 2012, found in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 8, 2013. Although we believe that the assumptions underlying the forward-looking statements contained in this Quarterly Report are reasonable, any of the assumptions could be inaccurate, and therefore there can be no assurance that such statements will be accurate. The risks, uncertainties and assumptions referred to above that could cause our results to differ materially from the results expressed or implied by such forward-looking statements include, but are not limited to, those discussed under the heading "Risk Factors" in Part II, Item 1A hereto and the risks, uncertainties and assumptions discussed from time to time in our other public filings and public announcements. All forward-looking statements included in this document are based on information available to us as of the date hereof. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that the results or conditions described in such statements or our objectives and plans will be achieved. Furthermore, past performance in operations and share price is not necessarily indicative of future performance. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Overview We develop and market low-power customizable semiconductor solutions that enable customers to add new differentiated features, extend battery life and improve the visual experience with their mobile, consumer and enterprise products. Our targeted mobile market segment includes Tablets, Smartphones and Mobile Enterprise. Our solutions typically fall into one of three product categories: Utilizing a focused customer engagement model, we market CSSPs to Original Equipment Manufacturers, or OEMs, and Original Design Manufacturers, or ODMs, that offer differentiated mobile products, and to processor vendors wishing to expand their served available market through the deployment of reference designs to their customers. Our solutions enable OEMs and ODMs to add new features, extend battery life and improve the visual experience of their handheld mobile devices. In addition to working directly with our customers, we partner with other companies with expertise in certain technologies to develop additional intellectual property, reference platforms and system software to provide application solutions. When we bring solutions to market with a partner company, we typically launch the solution as a Catalog CSSP. This enables us to sell the product as a 'catalog' device to any customer. In this manner, we are able to broaden the served available market for our CSSP solutions and leverage our R&D across multiple end customers. Table of Contents Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - (Continued) We also work with mobile processor manufacturers in the development of reference designs or "Catalog" CSSPs. Through reference designs that incorporate our CSSPs, we believe mobile processor manufacturers can expand the served available market for their processors. Furthermore, should a CSSP development for a processor manufacturer be applicable to a set of common OEMs or ODMs, we can amortize our R&D investment over that set of OEMs/ODMs. We call this type of solution a Catalog CSSP. The first such Catalog CSSP was developed in conjunction with Texas Instruments Incorporated, and introduced to the market during the second half of 2012. We are placing a greater emphasis on developing and marketing Catalog CSSPs in the future. In order to grow our revenue from its current level, we depend upon increased revenue from our new products including existing new product platforms and platforms currently in development. We expect our business growth to be driven by CSSPs and our CSSP revenue growth needs to be strong enough to enable us to sustain profitability while we continue to invest in the development, sales and marketing of our new solution platforms, PSBs and CSSPs. The gross margin associated with our CSSPs is generally lower than the gross margin of our FPGA products, due primarily to the price sensitive nature of the higher volume mobile consumer opportunities that we are pursuing with CSSPs. During the third quarter of 2013, we generated total revenue of $9.1 million which represents an increase of 77% over the prior quarter and an increase of 148% from the third quarter of 2012. Our new product revenue increased to $7.1 million, up 131% sequentially and up 358% year over year. The increase in new product revenue was primarily due to shipments of our ArcticLink III solution platform to Samsung. Revenue generated from Samsung accounted for 86% of our new product revenue and 68% of our total revenue. During the quarter, new products were shipped into the Tablet, Smartphone and the Mobile Enterprise markets. Our mature product revenue was $1.9 million, down 5% sequentially and down 8% year over year. Since we introduced CSSPs to the market in early 2007, we have devoted substantially all of our development, sales and marketing efforts on our new solution platforms, PSBs and CSSPs. We expect our revenue from mature products to continue to decline over time. Overall, we reported a net loss of $2.3 million for the third quarter of 2013. Critical Accounting Estimates The methods, estimates and judgments we use in applying our most critical accounting policies have a significant impact on the results we report in our consolidated financial statements. The SEC has defined critical accounting policies as those that are most important to the portrayal of our financial condition and results of operations and require us to make difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Based on this definition, our critical policies include revenue recognition, valuation of inventories including identification of excess quantities and product obsolescence, valuation of investments, valuation of long-lived assets, measurement of stock-based compensation and estimating accrued liabilities. We believe that we apply judgments and estimates in a consistent manner and that this consistent application results in consolidated financial statements and accompanying notes that fairly represent all periods presented. However, any factual errors or errors in these judgments and estimates may have a material impact on our financial statements. For a discussion of critical accounting policies and estimates, please see Item 7 in our Annual Report on Form 10-K for the fiscal year ended December 30, 2012, filed with the SEC on March 8, 2013. Table of Contents Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - (Continued) Results of Operations The following table sets forth the percentage of revenue for certain items in our statements of operations for the periods indicated: Three Months Ended September 29, September 30, 2013 2012 Revenue 100.0 % 100.0 % Cost of revenue 66.6 % 52.4 % Gross profit 33.4 % 47.6 % Operating expenses: Research and development 22.6 % 51.0 % Selling, general and administrative 35.4 % 72.7 % Restructuring costs (0.4 )% - % Income (loss) from operations (24.2 )% (76.1 )% Interest expense (0.1 )% (0.3 )% Interest income and other expense, net (0.8 )% 0.5 % Income (loss) before income taxes (25.1 )% (75.9 )% Provision for (benefit from) income taxes (0.2 )% 0.6 % Net Income (loss) (24.9 )% (76.5 )% Table of Contents Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - (Continued) Three Months Ended September 29, 2013 and September 30, 2012 Revenue The table below sets forth the changes in revenue for the three months ended September 29, 2013, as compared to the three months ended September 30, 2012 (in thousands, except percentage data): Three Months Ended September 29, 2013 September 30, 2012 Change % of Total % of Total Amount Revenues Amount Revenues Amount Percentage Revenue by product line (1): New products $ 7,139 79 % $ 1,558 43 % $ 5,581 358 % Mature products 1,927 21 % 2,099 57 % (172 ) (8 )% Total revenue $ 9,066 100 % $ 3,657 100 % $ 5,409 148 % _ (1) For all periods presented: New products represent products introduced since 2005, and include ArcticLink(R), ArcticLink II, ArcticLink III, Eclipse(TM) II, PolarPro(R), PolarPro II, and QuickPCI II. Mature products include Eclipse, EclipsePlus, pASIC(R) 1, pASIC 2, pASIC 3, QuickFC, QuickMIPS, QuickPCI, QuickRAM, and V3, as well as royalty revenue, programming hardware and software. The increase in new product revenue was primarily due to shipments to Samsung which has designed our ArcticLink III VX into a new tablet platform. Revenue generated from Samsung accounted for 86% of the new product revenue and 68% of total revenue in the third quarter of 2013. The decrease in mature product revenue is due primarily to reduced orders from our customers in the aerospace, test and instrumentation sectors. We continue to seek to expand our revenue through the pursuit of high volume sales opportunities in our target market segments and the sale of CSSPs incorporating our PSBs. Our industry is characterized by intense price competition and by lower margins as order volumes increase. While winning large-volume sales opportunities will increase our revenue, due to the pricing negotiation leverage of large companies, these opportunities may decrease our gross profit as a percentage of revenue. Gross Profit The table below sets forth the changes in gross profit for the three months ended September 29, 2013 as compared to the three months ended September 30, 2012 (in thousands, except percentage data): Three Months Ended September 29, 2013 September 30, 2012 Change % of Total % of Total Amount Revenues Amount Revenues Amount Percentage Revenue $ 9,066 100 % $ 3,657 100 % $ 5,409 148 % Cost of revenue 6,037 67 % 1,916 52 % 4,121 215 % Gross Profit $ 3,029 33 % $ 1,741 48 % $ 1,288 74 % The $1.3 million increase in gross profit in the third quarter of 2013 as compared to the third quarter of 2012 was mainly due to the increase in revenue, partially offset by the increase in inventory reserve of $130,000 and the increase in royalties of $231,000 in the third quarter of 2013. The decline in the gross margin percentage is due to the large concentration of our revenue from Samsung in the tablet market segment which is characterized by intense price competition and lower margins. Our semiconductor products have historically had long product life cycles and obsolescence has not been a significant factor in the valuation of inventories. However, as we pursue opportunities in the mobile market and continue to develop new CSSPs and products, we believe our product life cycle will be shorter and increase the potential for obsolescence. We also regularly review the cost of inventories against estimated market value and record a lower of cost or market reserve for inventories that have a cost in excess of estimated market value. This could have a material impact on our gross margin and Table of Contents Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - (Continued) inventory balances based on additional write-downs to net realizable value or a benefit from inventories previously written down. Operating Expenses The table below sets forth the changes in operating expenses for the three months ended September 29, 2013, as compared to the three months ended September 30, 2012 (in thousands, except percentage data): Three Months Ended September 29, 2013 September 30, 2012 Change % of Total % of Total Amount Revenues Amount Revenues Amount Percentage R&D expense $ 2,052 23 % $ 1,865 51 % $ 187 10 % SG&A expense 3,207 35 % 2,658 73 % 549 21 % Restructuring credits (32 ) - % - - % (32 ) - % Total operating expenses $ 5,227 58 % $ 4,523 124 % $ 704 16 % Research and Development Our research and development, or R&D, expenses consist primarily of personnel, overhead and other costs associated with engineering process improvements, programmable logic design, CSSP design and software development. The $187,000 increase in R&D expenses in the third quarter of 2013, as compared to the third quarter of 2012, was attributable primarily to a $217,000 increase in equipment and supplies and a $70,000 increase in compensation expenses. These expenses were partially offset by a $98,000 decrease in third party chip design costs. Selling, General and Administrative Expense Our selling, general and administrative, or SG&A, expenses consist primarily of personnel and related overhead costs for sales, marketing, finance, administration, human resources and general management. The $549,000 increase in SG&A expenses in the third quarter of 2013, as compared to the third quarter of 2012, was primarily due to a $472,000 increase in compensation expenses due to increased headcount and accrued executive bonuses; a $140,000 increase in outside services related to sales commissions; and a $140,000 increase in occupancy costs. These expenses were partially offset by a $153,000 decrease in stock-based compensation expenses. Restructuring Costs In an effort to consolidate and streamline its engineering organization, the Company implemented a restructuring plan on March 28, 2013. The net charges for employee severance benefits under this restructuring plan was $181,000 as of September 29, 2013. Interest Expense and Interest Income and Other Expense, Net The table below sets forth the changes in interest expense and interest income and other, net, for the three months ended September 29, 2013 as compared to the three months ended September 30, 2012 (in thousands, except percentage data): Three Months Ended Change September 29, September 30, 2013 2012 Amount Percentage Interest expense $ (8 ) $ (12 ) $ 4 (33 )% Interest income and other expense, net (74 ) 18 (92 ) (511 )% $ (82 ) $ 6 $ (88 ) (1467 )% The decrease in interest expense was due primarily to the reduction in interest accrued for leased design software tools in the third quarter of 2013 as compared to the third quarter of 2012. The change in interest income and other expense, net, was due primarily to foreign exchange fluctuations in the third quarter of 2013 as compared to the third quarter of 2012. Table of Contents Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - (Continued) We conduct a portion of our research and development activities in Canada and India and we have sales and marketing activities in various countries outside of the United States. Most of these international expenses are incurred in local currency. Foreign currency transaction gains and losses are included in interest and other income (expense), net, as they occur. We do not use derivative financial instruments to hedge our exposure to fluctuations in foreign currency and, therefore, our results of operations are, and will continue to be, susceptible to fluctuations in foreign exchange gains or losses. Provision for (Benefit from) Income Taxes The table below sets forth the changes in provision for income taxes for the three months ended September 29, 2013 as compared to the three months ended September 30, 2012 (in thousands, except percentage data): Three Months Ended Change September 29, September 30, 2013 2012 Amount Percentage Provision for (Benefit from) income taxes $ (18 ) $ 22 $ (40 ) (182 )% The income tax benefit for the third quarter of 2013 resulted from a reversal of a foreign tax accrual. The income tax provision for the third quarter of 2012 was primarily from our foreign operations which are cost-plus entities. As of the end of the third quarter of 2013, our ability to utilize our income tax loss carryforwards in future periods is uncertain and, accordingly, we recorded a full valuation allowance against the related U.S. tax provision. We will continue to assess the realizability of deferred tax assets in future periods. Table of Contents Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - (Continued) Nine Months Ended September 29, 2013 and September 30, 2012 Revenue The table below sets forth the changes in revenue for the nine months ended September 29, 2013 as compared to the nine months ended September 30, 2012 (in thousands, except percentage data): Nine Months Ended September 29, 2013 September 30, 2012 Change % of Total % of Total Amount Revenues Amount Revenues Amount Percentage Revenue by product line (1): New products $ 11,174 65 % $ 4,915 41 % $ 6,259 127 % Mature products 6,035 35 % 6,943 59 % (908 ) (13 )% Total revenue $ 17,209 100 % $ 11,858 100 % $ 5,351 45 % (1) For all periods presented: New products represent products introduced since 2005, and include ArcticLink(R), ArcticLink II, ArcticLink III, Eclipse(TM) II, PolarPro(R), PolarPro II, and QuickPCI II. Mature products include Eclipse, EclipsePlus, pASIC(R) 1, pASIC 2, pASIC 3, QuickFC, QuickMIPS, QuickPCI, QuickRAM, and V3, as well as royalty revenue, programming hardware and software. The increase in new product revenue was primarily driven by shipments of our ArcticLink III VX device to Samsung. Revenue generated from Samsung accounted for 76% of the new product revenue and 49% of the total revenue. The decrease in mature product revenue is due primarily to low bookings from our customers in the aerospace, test and instrumentation sectors. We continue to seek to expand our revenue through the pursuit of high-volume sales opportunities in the consumer market segment and the sale of CSSPs incorporating our PSBs. Our industry is characterized by intense price competition and by lower margins as order volumes increase. While winning large-volume sales opportunities will increase our revenue, we believe these opportunities may decrease our gross profit as a percentage of revenue. Gross Profit The table below sets forth the changes in gross profit for the nine months ended September 29, 2013 as compared to the nine months ended September 30, 2012 (in thousands, except percentage data): Nine Months Ended September 29, 2013 September 30, 2012 Change % of Total % of Total Amount Revenues Amount Revenues Amount Percentage Revenue $ 17,209 100 % $ 11,858 100 % $ 5,351 45 % Cost of revenue 11,210 65 % 6,313 53 % 4,897 78 % Gross Profit $ 5,999 35 % $ 5,545 47 % $ 454 8 % The $454,000 increase in gross profit in the first nine months of 2013 as compared to the first nine months of 2012 was mainly due to the increase in revenue, partially offset by the increase in royalty accruals of $278,000 in the first nine months of 2013. The decline in the gross margin percentage is due to the large concentration of our revenue from Samsung in the tablet market segment which is characterized by intense price competition and lower margins. Operating Expenses Table of Contents Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - (Continued) The table below sets forth the changes in operating expenses for the nine months ended September 29, 2013 as compared to the nine months ended September 30, 2012 (in thousands, except percentage data): Nine Months Ended September 29, 2013 September 30, 2012 Change % of Total % of Total Amount Revenues Amount Revenues Amount Percentage R&D expense $ 5,902 34 % $ 7,119 60 % $ (1,217 ) (17 )% . . . Nov 05, 2013 (c) 1995-2013 Cybernet Data Systems, Inc. All Rights Reserved Spirent Communications' (SPMYY) CEO Eric Hutchinson on Q2 2017 Results - Earnings Call Transcript | killexams.com 250-403 Real Questions and VCE Practice Test No result found, try new keyword!In Lifecycle Service Assurance, the reduction in lab test pending ahead of the shift into live ... to support new product launches and further develop our key account management. Administration costs ... Direct Download of over 5500 Certification Exams References : Dropmark : http://killexams.dropmark.com/367904/11889542 Wordpress : http://wp.me/p7SJ6L-22o Dropmark-Text : http://killexams.dropmark.com/367904/12875363 Blogspot : http://killexamsbraindump.blogspot.com/2017/12/symantec-250-403-dumps-and-practice.html RSS Feed : http://feeds.feedburner.com/WhereCanIGetHelpToPass250-403Exam Box.net : v


Free PDF Download

References:


Free Download 250-403 PDF Dumps
Free Download Killexams Certification Exam Dumps
Killexams Certification Exam Questions and Answers - amongtheway
Killexams Exam Study Notes, study guides - www.amongtheway.com
Killexams Certification Exam Questions and Answers - st.edu
Killexams Exam Study Notes, study guides - st.edu
Killexams Certification Exam Questions and Answers - Puntotecnia
Killexams Exam Study Notes, study guides - Puntotecnia
Killexams Certification Exam Questions and Answers
Killexams Exam Study Notes, study guides
Killexams Certification Exam Questions and Answers and Study Notes
Killexams Exam Study Notes, study guides, QA
Killexams Exam Study Notes
Killexams Certification Exam Study Notes
Killexams Certification Exam Study Notes
Killexams Certification Exam Study Notes
Download Hottest Killexams Certification Exams - CSCPK
Here you will find Real Exam Questions and Answers of every exam - dinhvihaiphong.net
Study notes to cover complete exam syllabus - Killexams.com
Killexams Exams Download Links - nrnireland.org
Killexams Study Guides and Exam Simulator - simepe.com.br
Killexams Study Guides and Exam Simulator - skinlove.nl
Killexams Study Guides and Exam Simulator - marinedubai.com/


www.pass4surez.com (c) 2017-2021